WHO endorses GLP-1s for some obese youth: what Canada's regulators and clinicians need to know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

The World Health Organization (WHO) published its first-ever international guidelines on childhood obesity on October 7, 2026, conditionally recommending GLP-1 receptor agonist medications for youth aged 10 to 19 when a supervised lifestyle program has not produced results. For Canadian families, the practical question is immediate: Health Canada has already approved two GLP-1s for weight management in adolescents aged 12 and older, yet provincial drug plans across the country largely do not cover these medications for pediatric patients, leaving most costs to private insurance or direct out-of-pocket payment.

The WHO's guidance covers roughly 170 million children and teenagers worldwide between the ages of five and 19 who were living with obesity in 2024, a figure the agency says has quadrupled since 1990. The guidelines draw a firm line at age nine: no medication, surgery, or weight-loss device is recommended for children up to that age. For youth 10 to 19, GLP-1s and other pharmacological options enter the picture only after structured lifestyle support has been tried. The WHO also flagged that the overall evidence base for these medications in children is "generally of low quality due to short-term follow-up" and small study populations.

What this means in Canada

Health Canada has approved semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for weight management) and liraglutide (Saxenda) for adolescent weight management starting at age 12. A generic version of semaglutide was also approved by Health Canada in 2026, which may reduce costs modestly. The Canadian Medical Association Journal (CMAJ) published updated Canadian pediatric obesity guidelines in 2025, and those guidelines differ from the WHO's in one notable way: Canadian physicians do not require that lifestyle interventions fail before medication can be considered. The CMAJ guidance states explicitly that "there is no evidence to support a stepwise approach whereby pharmacologic and surgical interventions should be offered only if behavioural and psychological interventions prove ineffective," and calls instead for shared decision-making between clinicians and families.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a specific position statement on pediatric GLP-1 use. Obesity Canada, a national advocacy and research organization, has been active in pushing for improved access and reduced stigma in obesity care, including for younger patients.

On provincial coverage: as of October 2026, no major provincial formulary, including OHIP in Ontario, RAMQ in Quebec, MSP in British Columbia, or AHCIP in Alberta, routinely covers GLP-1s for pediatric obesity. Some children with concurrent type 2 diabetes may access semaglutide through diabetes-related coverage pathways, but weight management indications for youth remain largely unfunded publicly. Dr. Marina Ybarra, a pediatric endocrinologist at the London Health Sciences Centre Children's Hospital and Western University, told CBC News that her patients typically pay through parental private insurance or out of pocket, and that WHO recognition of GLP-1s as a legitimate treatment tool is her "biggest hope" for eventually securing public funding.

What changed

Before October 7, 2026, no international body had issued consolidated global guidance on managing childhood obesity. The WHO's publication fills that gap and gives clinicians, health ministries, and payers a reference point that did not previously exist at the global level.

The guidelines arrive alongside a dramatic shift in prescribing patterns. A study published in the journal Pediatrics in September 2026 documented a 310-fold increase in GLP-1 prescriptions for children aged eight to eleven in the United States between 2019 and 2026, rising from 0.03 percent to more than nine percent of that age group, though absolute numbers remain small. Canadian prescribing data at the same granularity are not yet publicly available, but the trend is directionally consistent with what Canadian pediatric weight management clinics are reporting anecdotally.

Novo Nordisk (Denmark) and Eli Lilly (US) are both running pediatric trials of their GLP-1 products in children as young as six. The WHO declined to speculate on how those trial results might alter future recommendations.

What Canadian patients and families should know

If your child is 12 or older and living with obesity, a Canadian physician can legally prescribe Wegovy or Saxenda. The conversation about whether to do so should involve a pediatric endocrinologist or a physician with training in obesity medicine, not a general telehealth consult. Canadian telehealth platforms such as Felix, Maple, and Telus Health offer GLP-1 prescribing for adults, but pediatric prescribing through these platforms is not standard practice and families should seek specialist referral.

Cost is a real barrier. Wegovy listed at roughly $400 to $500 CAD per month before the generic semaglutide approval; generic pricing may bring that down, but it is still significant for most families without comprehensive private drug coverage. Families can ask their physician about compassionate access programs offered by manufacturers, though eligibility criteria vary.

For children under 12, or under 10 in particular, neither the WHO nor Health Canada supports GLP-1 use for weight management at this time. The CMAJ 2025 guidelines apply to children 12 and older. Parents who encounter online or cross-border sources offering GLP-1s for younger children should be aware that no Canadian regulatory approval exists for that age group in this indication.

The WHO guidelines do not change what a Canadian physician can prescribe today. They may, over time, influence Health Canada's review of age indications and provincial formulary decisions, but that process takes years.

Limitations and open questions

The WHO itself acknowledged the evidence base is thin. Most pediatric GLP-1 trials have short follow-up periods and small sample sizes. Long-term data on bone density, growth, pubertal development, and psychological outcomes in adolescents using these drugs for years are not yet available.

The WHO also flagged specific risk populations: youth with eating disorders and athletes, where GLP-1-driven appetite suppression could cause harm rather than benefit. Canadian clinicians are advised to screen carefully before initiating treatment.

Health Canada has not issued updated pediatric-specific prescribing guidance in response to the WHO publication. The SOGC has not yet issued a position statement on GLP-1 use in pediatric patients. Whether provincial formularies will move toward coverage in light of WHO endorsement is unknown; historically, such policy shifts in Canada take multiple years and require health technology assessments by bodies such as the Canadian Drug Agency (formerly CADTH).

What the WHO's guidelines do accomplish is place pediatric GLP-1 use on the formal international agenda. Whether that translates into funded, accessible care for Canadian children living with obesity depends on decisions that Health Canada, provincial health ministries, and Canadian clinical societies have not yet made.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.